Protocol reference
Peptide Cycle Length: On-Cycle & Off-Cycle Basics
By Baris Bingor · Last updated
How long is a peptide cycle?
There is no FDA-approved or universal peptide cycle length — durations come from study designs and community convention, and they vary by compound and goal. Research-healing peptides like BPC-157 and TB-500 are commonly described in defined blocks of several weeks followed by a break, while GLP-1 peptides such as semaglutide are chronic, continuous therapy — not 'cycled.' Any cycle decision belongs with a licensed clinician; Peptly only tracks the schedule you set.
There is no official cycle length
The first thing to be clear about: for research peptides there is no approved, standardized cycle length. The week counts that circulate online come from two places — the fixed durations used in clinical or animal studies, and community convention that borrows those numbers. Neither is a dosing recommendation, and neither replaces individualized medical guidance. This page explains the framing people use; it does not tell you how long to run anything.
What "on-cycle" and "off-cycle" mean
"On-cycle" is the period during which a compound is being used; "off-cycle" is the break afterward. The vocabulary is borrowed from broader performance and research culture. The idea behind a defined window is simply that a protocol has a start, a planned duration, and a stop — after which the user (ideally with a clinician) reassesses before deciding whether to repeat.
Cycled vs continuous: it depends on the peptide
The single most important distinction is that not every peptide is "cycled" at all. The framing differs sharply by class:
| Peptide class (examples) | Common framing |
|---|---|
| Repair / recovery (BPC-157, TB-500) | Community protocols describe defined multi-week blocks with a break afterward |
| GH secretagogues (CJC-1295, ipamorelin) | Often described as longer, sometimes continuous research use |
| GLP-1 agonists (semaglutide, tirzepatide) | Chronic, continuous therapy — not cycled |
The healing-peptide blocks people cite (commonly somewhere in the range of several weeks on, then a comparable break) are convention, not a rule — they vary widely between sources and individuals.
The GLP-1 exception: continuous, not cycled
GLP-1 receptor agonists — semaglutide, tirzepatide and the like — are the clearest case where cycling is the wrong mental model. These are chronic medications. The clinical literature is consistent that stopping them tends to be followed by weight regain, and restarting requires re-titrating the dose back up from a low starting point to manage side effects. Running them in "8-week cycles with breaks" works against how they function. If a GLP-1 is involved, the realistic pattern is continuous use under medical supervision, not on/off blocks. (See also the GLP-1 dose calculator and tirzepatide vs semaglutide.)
Why breaks appear in many protocols
Where breaks are used, the stated reasons are reassessment and giving the body a defined pause rather than open-ended use. Community sources often suggest an off period roughly equal to the on period. Treat this as a convention to discuss with a clinician, not as evidence-based guidance — the supporting data for specific break lengths in research peptides is thin.
What the research literature actually shows
When you see a "cycle length" attached to a peptide, it is usually traceable to a study that dosed for a fixed number of weeks. That window was chosen to measure an endpoint — healing, weight change, a biomarker — over a defined period. It tells you how long the study ran, not how long an individual should use the compound. Durations across the literature vary widely, which is exactly why no single "correct" cycle length exists.
Tracking a cycle in Peptly
Peptly does not recommend a cycle length — it tracks the one you set. Log the start of a cycle, each dose as you take it (against a saved reconstitution mix), and the break afterward; the History view shows the whole timeline, and reminders keep a schedule you have decided on with a clinician. The app's job is the arithmetic and the record, not the medical decision.
See also
- Peptide half-life — why dosing frequency varies
- Peptide tracker — injection log
- Peptide storage & refrigeration guide
- How to reconstitute peptides
- Peptide dosage unit reference
Frequently asked questions
Is there a standard peptide cycle length? +
No. There is no FDA-approved or universal standard cycle length for research peptides. The durations people cite come from study designs and community convention, and they vary by compound, goal, and individual. Any cycle decision should be made with a licensed clinician — Peptly is a calculator and reference, not medical advice.
Do you cycle GLP-1 peptides like semaglutide? +
No. GLP-1 receptor agonists such as semaglutide and tirzepatide are chronic, continuous therapy, not "cycled." Stopping and restarting typically leads to weight regain and forces dose re-titration, so the clinical pattern is ongoing use under medical supervision, not on/off blocks.
How long are off-cycle breaks? +
In community protocols, the off-cycle break is often described as roughly matching the on-cycle length — for example a break similar in length to the time on. This is convention, not an approved rule, and its stated purpose is reassessment. Discuss any break schedule with a clinician.
Why do research studies use fixed cycle durations? +
A clinical or animal study runs for a defined period because that is the experimental design — it measures an outcome over a set window. That duration is a study-design choice, not a dosing recommendation for individuals, even though community protocols often borrow those numbers.
Does Peptly recommend a cycle length? +
No. Peptly never recommends a dose or a cycle length. It tracks the schedule you set — cycle start, each logged dose, and breaks — so you can follow a plan you have made with a clinician. The math and the log are the product; the medical decisions are not.